Tag Archives: ATLAS-2M study

ViiV Healthcare begins phase III study on long-acting two-drug regimen in virally suppressed adults with HIV-1 infection

The ATLAS-2M study will evaluate injections every two months in virally suppressed patients LONDON, 29-Nov-2017 — /EuropaWire/ — Today (27 November 2017) ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, … Read the full press release